A therapy for polyglutamine (polyq) diseases
AssigneeSteminent Biotherapeutics Inc.
InventorsJennifer Hui-Chun HO, Ryan CHANG, Hsiu-Yu LAI, Wei-Kee ONG
Life of this patent
Estimating the term…
Abstract
Provided are methods and articles of manufacture for use in stem cell therapy, for the treatment of diseases or conditions of SCA. Particularly, the invention provides a method for treating SCA, comprising parenterally or locally administering an effective amount of stem cells as a unit dosage to a subject, wherein the administration is performed with one or more treatment cycles, wherein one treatment cycle comprises dosing three unit dosages each at a dosing interval of two to six weeks.
Claims17
A method for treating a polyglutamine (polyQ) disease in a subject, comprising parenterally or locally administering an effective amount of stem cells as a unit dosage to a subject, wherein the administration is performed with one or more treatment cycles, wherein one treatment cycle comprises dosing three unit dosages each at a dosing interval of two to six weeks.
17-38. (canceled)
Dependencies are inferred from the claim text.